For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Travere Therapeutics Inc (NASDAQ: TVTX) closed at $34.58 down -2.87% from its previous closing price of $35.6. In other words, the price has decreased by -$2.87 from its previous closing price. On the day, 2.88 million shares were traded. TVTX stock price reached its highest trading level at $36.07 during the session, while it also had its lowest trading level at $33.92.
Ratios:
For a deeper understanding of Travere Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.75. In the meantime, Its Debt-to-Equity ratio is 4.48 whereas as Long-Term Debt/Eq ratio is at 4.40.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on October 31, 2025, Reiterated its Buy rating but revised its target price to $48 from $34 previously.
Citigroup reiterated its Buy rating for the stock on June 11, 2025, while the target price for the stock was revised from $35 to $32.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’26 when Inrig Jula sold 2,031 shares for $40.18 per share. The transaction valued at 81,606 led to the insider holds 86,756 shares of the business.
Inrig Jula sold 445 shares of TVTX for $16,799 on Jan 06 ’26. The CHIEF MEDICAL OFFICER now owns 86,311 shares after completing the transaction at $37.75 per share. On Jan 06 ’26, another insider, JULA INRIG, who serves as the Officer of the company, bought 445 shares for $37.75 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 3093953280 and an Enterprise Value of 3169171968. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.31 while its Price-to-Book (P/B) ratio in mrq is 42.05. Its current Enterprise Value per Revenue stands at 7.272 whereas that against EBITDA is -90.462.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.84, which has changed by 0.86013985 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $42.13, while it has fallen to a 52-week low of $12.91. The 50-Day Moving Average of the stock is -2.05%, while the 200-Day Moving Average is calculated to be 50.00%.
Shares Statistics:
For the past three months, TVTX has traded an average of 1.88M shares per day and 2024620 over the past ten days. A total of 89.46M shares are outstanding, with a floating share count of 87.75M. Insiders hold about 1.93% of the company’s shares, while institutions hold 117.24% stake in the company. Shares short for TVTX as of 1765756800 were 12196281 with a Short Ratio of 6.50, compared to 1763078400 on 10355808. Therefore, it implies a Short% of Shares Outstanding of 12196281 and a Short% of Float of 13.73.
Earnings Estimates
A comprehensive evaluation of Travere Therapeutics Inc (TVTX) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.07, with high estimates of $0.23 and low estimates of -$0.07.
Analysts are recommending an EPS of between $1.06 and $0.53 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is $1.82, with 7.0 analysts recommending between $2.98 and $0.73.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $142.18M this quarter.It ranges from a high estimate of $184M to a low estimate of $122.37M. As of. The current estimate, Travere Therapeutics Inc’s year-ago sales were $74.79MFor the next quarter, 13 analysts are estimating revenue of $133.51M. There is a high estimate of $144.7M for the next quarter, whereas the lowest estimate is $119.57M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $545M, while the lowest revenue estimate was $483.3M, resulting in an average revenue estimate of $502.96M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $689.06M in the next fiscal year. The high estimate is $802.8M and the low estimate is $580M.
